|
First author | Publication year | Cellular type | Object | Delivery method | Duration of observation | Clinical parameters |
|
Dash | 2009 | Autologous BM-MSCs | 24 patients with nonhealing ulcers of the lower limb (diabetic foot ulcers and Buerger disease) | Autologous cultured BM-derived MSCs along with standard wound dressing | 12 weeks | Decrease in wound size, increase in pain-free walking distance, maintain normal liver and renal function, improve leg perfusion sufficiently |
|
Amann | 2009 | Autologous BM-MSCs | 51 patients with impending major amputation due to severe critical limb ischemia | Intramuscular transplantation | 6 months | Improve leg perfusion sufficiently to reduce major amputations and permit durable limb salvage, reduce analgesics consumption, increase in pain-free walking distance |
|
Vojtassak | 2006 | Autologous biograft composed of autologous skin fibroblasts on biodegradable collagen membrane (Coladerm) in combination with autologous BM-MSCs | Patients with diabetic foot | Directly to the wound and injected into the edges of the wound, finally covered with prepared autologous biograft, received two additional treatments with cultured MSC on days 7 and 17 | 29 days | Decrease in wound size and an increase in the vascularity of the dermis and in the dermal thickness of the wound bed |
|
Lu | 2011 | Autologous BM-MSCs | 41 type 2 diabetic patients with bilateral critical limb ischemia and foot ulcer | Intramuscular injection | 24 weeks | Increase in pain-free walking distance, improve leg perfusion, ankle-brachial index (ABI), transcutaneous oxygen pressure (TcO2), magnetic resonance angiography (MRA) analysis |
|
Procházka | 2010 | Autologous BM-MSCs | 96 patients with critical limb ischemia and foot ulcer | Inject into the ischemic limb along the posterior and anterior tibial artery | 120 days | 79% limb salvage in patients |
|
Li | 2013 | Allogeneic UCB-MSCs | 15 diabetic patients with foot disease | 10 mL is injected intramuscularly into impaired lower limbs and 2 mL is delivered into the basilar portions of foot ulcers and the surrounding subcutaneous tissues | 12 weeks | Weakness, numbness, pain, cold feeling, or intermittent limp, skin temperature, ABI, and transcutaneous oxygen pressure (TcO2) are improved |
|